- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.07. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.07. | Reviva Pharmaceuticals: Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension | 150 | GlobeNewswire (Europe) | - Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary... ► Artikel lesen | |
| 29.05. | Reviva Pharmaceuticals: Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 3 | GlobeNewswire (USA) | ||
| 29.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 28.05. | Reviva Pharmaceuticals looks to raise $3M through direct offering; shares fall | 2 | Seeking Alpha | ||
| 21.05. | Reviva Pharmaceuticals: Reviva to Participate in the BIO International Convention | 1 | GlobeNewswire (USA) | ||
| 17.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 14.05. | Reviva Pharmaceuticals Holdings, Inc. reports results for the quarter ended in March - Earnings Summary | 2 | Reuters | ||
| 14.05. | Reviva Pharmaceuticals GAAP EPS of -$0.25 | 3 | Seeking Alpha | ||
| 14.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Reviva Pharmaceuticals: Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference | 2 | GlobeNewswire (USA) | ||
| 15.04. | Reviva Pharmaceuticals FY Non-GAAP EPS of -$1.65 beats by $0.01 | 3 | Seeking Alpha | ||
| 15.04. | Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment | 2 | Seeking Alpha | ||
| 15.04. | Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia | 388 | GlobeNewswire (Europe) | - FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA)... ► Artikel lesen | |
| 15.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 15.04. | Reviva Pharmaceuticals: Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights | 474 | GlobeNewswire (Europe) | - RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia - - Initiation of... ► Artikel lesen | |
| 15.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 4 | SEC Filings | ||
| 26.03. | Reviva Pharmaceuticals: Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting | 9 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRONOS GROUP | 2,202 | -1,43 % | Cronos Group Inc: Cronos to hold Q2 results call Aug. 8 | ||
| GREEN THUMB INDUSTRIES | 10,260 | +0,79 % | Green Thumb Industries Inc: Green Thumb Industries expands Beboe brand to New York | ||
| ASTRIA THERAPEUTICS | 11,300 | +2,73 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress | Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 0,554 | -4,40 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya for Fibromyalgia | Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need Fast Track designation for Tonmya recognizes fibromyalgia as a serious... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 8,330 | -0,48 % | wO Community-Rückblick: wO-User zu Newron Pharma: "Ohne Big Player sind wir am Arsch - das ist Fakt!" | © Foto: Hardy Schilling - wallstreetONLINEDer Kurs von Newron Pharmaceuticals dümpelt nach dem dem Kursrutsch Ende Juni vor sich hin und die Stimmung in der Newron Community changiert zwischen Sorge... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 2,326 | -0,13 % | Oramed Pharmaceuticals Inc.: Oramed Letter to Shareholders | Stock Repurchase Program
Scilex Senior Secured Note
Phase 3 Oral Insulin Trial in US
JV with Chinese Partner, HTIT
NEW YORK, June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq:... ► Artikel lesen | |
| CASSAVA SCIENCES | 13,760 | +0,15 % | Buy Aehr Test Systems, Sell Cassava Sciences | ||
| CATALYST PHARMACEUTICALS | 16,100 | -0,59 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE in Canada | CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 5,028 | -0,12 % | ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal | SEOUL, South Korea, June 7, 2024 /PRNewswire/ --
Dear Fellow Shareholders,
ILJIN SNT Co., Ltd. ("ILJIN") is a long-standing investor of Aurinia Pharmaceuticals Inc. ("Aurinia" or... ► Artikel lesen | |
| ROCKET LAB USA | 5,040 | +1,41 % | Mynaric AG: Mynaric Selected by Rocket Lab for Space Development Agency's Tranche 2 Transport Layer - Beta Program | Laser Communications Manufacturer Expands Customer RosterLOS ANGELES, CA / ACCESSWIRE / May 7, 2024 / Mynaric (NASDAQ:MYNA)(FRA:M0YN), a leading provider of industrialized, cost-effective and scalable... ► Artikel lesen | |
| AGILE THERAPEUTICS | 0,580 | -3,69 % | Agile Therapeutics, Inc.: Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L. | Agile Therapeutics will combine with Insud Pharma's US Subsidiary, Exeltis, expanding an already significant Women's Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 0,430 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation | Encinitas, California--(Newsfile Corp. - July 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), today announced that Eric Daniels, M.D., Chief Development Officer... ► Artikel lesen | |
| BOIRON | 31,800 | 0,00 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| LIPOCINE | 5,570 | -4,30 % | Lipocine Inc.: Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 | SALT LAKE CITY, June 10, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were featured in a late breaking... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 0,403 | -3,20 % | Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics |
Das Unternehmen REVIVA PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,020 (-1,59 %) liegt der Kurs bei 1,240 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.
